14th week of 2016 patent applcation highlights part 16 |
Patent application number | Title | Published |
20160096782 | METHODS AND APPARATUSES FOR PROCESSING BIO-DERIVED NORMAL NONANE - Methods for forming bio-derived fuel products, upgrading bio-derived feedstocks, and processing bio-derived normal nonane are provided. In an embodiment, a method for forming a bio-derived fuel product includes providing a bio-derived hydrocarbon stream comprising at least about 50 wt % normal nonane and having a research octane number of less than about 10. The method further includes isomerizing the bio-derived hydrocarbon stream over a non-zeolitic, non-sulfated and/or non-halogenated catalyst to form the bio-derived fuel product with a research octane number of greater than about 50. | 2016-04-07 |
20160096783 | POLYOLEFIN MANUFACTURING SYSTEM INCLUDING A MEMBRANE FRACTIONATION SYSTEM FOR DILUENT RECOVERY - A fractionation system for a polymerization reactor includes a membrane separation system designed to separate light components, such as unreacted monomer and inerts, from diluent. The membrane separation system may employ one or more membrane modules designed to separate hydrocarbons based on size, solubility, or combinations thereof. The fractionation system also may include a heavies fractionation column designed to separate heavy components, such as unreacted comonomer and oligomers, from the diluent. | 2016-04-07 |
20160096784 | Separations With Ionic Liquid Solvents - Disclosed are systems and methods which provide a process stream comprising a gaseous component, capture the gaseous component from the process stream by an ionic liquid solvent of a separator, and recover a captured gaseous component from the ionic liquid solvent in a regenerator. A second gaseous component from the process stream may be captured by the ionic liquid solvent of the separator, and the second gaseous component may be recovered from the ionic liquid solvent in the regenerator. Alternatively, the second gaseous component from the process stream may be uncaptured by the ionic liquid solvent, and the uncaptured second gaseous component may be recovered from a membrane unit. | 2016-04-07 |
20160096785 | SELECTIVE HYDROGENATION PROCESS - A process for reducing the diene content of an olefin by feeding hydrogen to the process in stages. | 2016-04-07 |
20160096786 | Method to Improve Halogenation Reactions - In the halogenation reaction of olefin/halo-olefin (i.e., organic), an excess amount of halogen gas (fluorine, chlorine, vaporized bromine and iodine, or their combination) is normally used in order to achieve as complete as possible conversion of the organic. In a conventional process, the excess halogen gas in the off-gas stream is scrubbed by caustic solution which increases the consumption of halogen and generates waste for disposal. The present invention provides a novel process to recover and reuse the excess halogen gas and thus reduce the operating cost of the process. | 2016-04-07 |
20160096787 | METHOD FOR PREPARING 2,3,3,3-TETRAFLUOROPROPENE - A method for preparing 2,3,3,3-tetrafluoropropene, including: a) heating and vaporizing hydrogen fluoride and 1,1,2,3-tetrachloropropene (TCP), and introducing hydrogen fluoride and TCP to a first reactor for reaction in the presence of an A-type catalyst to yield a first product mixture including 2,3-dichloro-3,3-difluoropropene (“HCFO-1232xf”), where the mole ratio between hydrogen fluoride and TCP is between 5:1 and 60:1, the reaction temperature is between 200 and 500° C., and the space velocity is between 200 and 2000 h | 2016-04-07 |
20160096788 | LIQUID CRYSTAL COMPOSITION HAVING A NEGATIVE LIQUID CRYSTAL MODE - Provided is a liquid crystal composition including an additive of the following chemical formula: | 2016-04-07 |
20160096789 | PROCESS FOR THE PREPARATION OF MONOETHYLENE GLYCOL - The invention provides a process for the preparation of monoethylene glycol from sucrose comprising the steps of: i) hydrolysing sucrose to form a reaction product stream comprising glucose and fructose; ii) separating the reaction product stream comprising glucose and fructose into a fructose or fructose derivative rich stream and a glucose rich stream; and iii) contacting the glucose rich stream with hydrogen in a reactor in the presence of a solvent and a catalyst system with catalytic hydrogenation abilities to produce a product stream comprising monoethylene glycol. | 2016-04-07 |
20160096790 | PROCESS FOR THE SEPARATION OF 1,4-BUTANEDIOL - The invention provides a process for the recovery of 1,4-butanediol from an aqueous stream, said process comprising the steps of providing the aqueous stream, providing a first solvent stream, combining said aqueous stream with said first solvent stream and recovering at least a portion of the 1,4-butanediol by liquid-liquid extraction. | 2016-04-07 |
20160096791 | DIRECT ANTI-MARKOVNIKOV ADDITION OF ACIDS TO ALKENES - A method of making an anti-Markovnikov addition product, comprises reacting an acid with an alkene or alkyne in a dual catalyst reaction system to the exclusion of oxygen to produce said anti-Markovnikov addition product; the dual catalyst reaction system comprising a single electron oxidation catalyst in combination with a hydrogen atom donor catalyst. Dual catalyst composition useful for carrying out such methods are also described. | 2016-04-07 |
20160096792 | CATALYSTS AND METHODS FOR ALCOHOL DEHYDRATION - Provided is a method for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a halogenated rare earth element oxide catalyst, wherein the used dehydration catalyst may be regenerated by a halogenation step. The rare earth element oxide is an oxide of a light rare earth element, an oxide of a medium rare earth element, an oxide of a heavy rare earth element, an oxide of yttrium, or a mixtures of two or more thereof. | 2016-04-07 |
20160096793 | SYSTEMS AND METHODS FOR GAS TREATMENT - A system and process for the recovery of at least one halogenated hydrocarbon from a gas stream. The recovery includes adsorption by exposing the gas stream to an adsorbent with a lattice structure having pore diameters with an average pore opening of between about 5 and about 50 angstroms. The adsorbent is then regenerated by exposing the adsorbent to a purge gas under conditions which efficiently desorb the at least one adsorbed halogenated hydrocarbon from the adsorbent. The at least one halogenated hydrocarbon (and impurities or reaction products) can be condensed from the purge gas and subjected to fractional distillation to provide a recovered halogenated hydrocarbon. | 2016-04-07 |
20160096794 | CATALYST SYSTEM FOR PRODUCING KETONES FROM EPOXIDES - A catalyst composition is useful for producing a ketone from a compound containing at least one epoxide group, and the catalyst composition contains at least one precious metal; and at least one mixed oxide; wherein the mixed oxide contains zirconium dioxide and silicon dioxide; wherein the precious metal is supported and the support is not entirely made of the mixed oxide; and wherein a mass ratio of zirconium dioxide to silicon dioxide in the mixed oxide is 86:14 to 99.9:0.1. | 2016-04-07 |
20160096795 | COMPOUNDS AND METHODS FOR PREPARATION OF DIARYLPROPANES - Compounds of structure (I): | 2016-04-07 |
20160096796 | PRODUCTION OF PRODUCTS FROM NATURAL RESOURCES - The method disclosed herein relates to two stage catalytic processes for converting syngas to acetic acid, acrylic acid and/or propylene. More specifically, the method described and claimed herein relate to a method of producing acrylic acid and acetic acid comprising the steps of: a) providing a feedstream comprising syngas; b) contacting the feedstream with a first catalyst to produce a first product stream comprising C | 2016-04-07 |
20160096797 | METHOD OF SEPARATING LACTIC ACID OR SALT THEREOF - Provided is a method of separating lactic acid or a salt thereof. The method includes removing a coloring material, including hydroxymethylfurfural (HMF), from a fermentation broth, which includes at least one of lactic acid and a salt thereof; and recovering lactic acid or a salt thereof from the fermentation broth, from which the coloring material has been removed. | 2016-04-07 |
20160096798 | METHOD FOR PURIFYING DIOCTYL PHTHALATE - Disclosed is a method of reducing the ultraviolet-light absorbing properties of a composition comprising dioctyl phthalate, the method comprising (a) obtaining a composition comprising dioctyl phthalate and phthalide, wherein said composition has an absorbance of greater than 0.1 at a wavelength of about from 230 to 360 nm, (b) contacting the composition with activated carbon, silica gel, or diatomaceous earth, for a sufficient amount of time to allow the phthalide to contact the activated carbon, silica gel, or diatomaceous earth, and (c) removing the composition from the activated carbon, silica gel, or diatomaceous earth, wherein the composition obtained from step (c) has an absorbance equal to or less than about 0.1 at a wavelength of about from 230 to 360 nm and has a reduced amount of phthalide when compared with the composition from step (a). | 2016-04-07 |
20160096799 | OLIGOMER-AMINO ACID CONJUGATES - The invention relates to (among other things) oligomer-amino acid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated amino acid compounds. | 2016-04-07 |
20160096800 | MODULATORS OF THE EIF2ALPHA PATHWAY - Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2α phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory. | 2016-04-07 |
20160096801 | Modularized System and Method for Urea Production Using Stranded Natural Gas - A modular system and method for producing urea from stranded natural gas includes removal of foreign particulate matter to obtain a substantially homogeneous gas. The gas is processed by controlling the quality of the stranded natural gas to maintain a substantially homogenous mixture The resultant gas stream is further cleaned and compressed to a high pressure of about 3,000 psi. The resultant ammonia stream is processed in a bypass recycling loop system at 30% conversion rate at a high pressure of about 6,000 to 7,000 psi. The equipment associated with each of the process steps may be skid mounted for portability and/or contained within the footprint of a standard 48-foot flatbed trailer. | 2016-04-07 |
20160096802 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS - A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound. | 2016-04-07 |
20160096803 | CRYSTAL OF PYRROLE DERIVATIVE AND METHOD FOR PRODUCING THE SAME - The present invention provides a production intermediate of an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, a method for producing the same, and a crystal thereof. A method for producing an atropisomer of a pyrrole derivative including a step of resolving a compound represented by the following general formula (I) [wherein R | 2016-04-07 |
20160096804 | NOVEL HISTONE DEACETYLASE INHIBITORS - The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors. | 2016-04-07 |
20160096805 | KINASE INHIBITOR - There is provided a compound of formula I, | 2016-04-07 |
20160096806 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition - Various 2-aminoquinoline compounds as can be used, in vivo or in vitro, for selective inhibition of neuronal nitric oxide synthase. | 2016-04-07 |
20160096807 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits. | 2016-04-07 |
20160096808 | METHODS OF RESOLVING RACEMIC MIXTURE TO OBTAIN (-)-HUPERZINE A - A method of resolving a racemic mixture of (±)-Huperzine A to (−)-Huperzine A includes: separating the (−)-Huperzine A from the racemic mixture of (±)-Huperzine A by chiral high performance liquid chromatography (HPLC), the chiral HPLC being performed utilizing a mobile phase including a solution including an alcohol and one selected from dichloromethane, trichloromethane, and a mixture thereof, and the chiral HPLC being performed utilizing a chiral stationary phase including a polysaccharide derivative. | 2016-04-07 |
20160096809 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES - The present invention relates to fluorene derivatives and to electronic devices in which these compounds are used as matrix material in the emitting layer and/or as hole-transport material and/or as electron-blocking or exciton-blocking material and/or as electron-transport material. | 2016-04-07 |
20160096810 | ENANTIOSELECTIVE SYNTHESIS OF DIALKYLATED N,O-HETEROCYCLES BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION - This invention provides enantioenriched N,O-heterocyclic compounds with quaternary stereogenic centers and novel methods of preparing the compounds. Methods include the method for the preparation of a compound of formula (I): | 2016-04-07 |
20160096811 | BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS - Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D | 2016-04-07 |
20160096812 | TREATMENT OF CANCER/INHIBITION OF METASTASIS - Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole. | 2016-04-07 |
20160096813 | TETRAHYDROFURAN-2,5-DICARBALDEHYDES (DIFORMYL-TETRAHYDROFURAN, DFTHF) AND PROCESS FOR MAKING THE SAME - Tetrahydrofuran-(THF)-2,5-dicarbaldehyde and a process of preparing the same are described. The process involves reacting THF-diols in an inert organic solvent with an oxidizing agent at a temperature up to about 50 C. The process can use either HMF or THF-diols as starting materials, and enables a single-step conversion of THF-diols into a precursor material that can be transformed into a multitude of furanic derivative compounds. THF dicarbaldehyde can be modified according to certain reaction processes to generate either new or existing derivative compounds. | 2016-04-07 |
20160096814 | METHOD FOR PRODUCING DEHYDRO ROSE OXIDE - The present invention relates to a method for producing dehydro rose oxide by reacting isoprenol and prenal in the presence of at least one sulfonic acid of formula R | 2016-04-07 |
20160096815 | T-TYPE CALCIUM CHANNEL INHIBITOR - The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action. (In formula (1), each of R | 2016-04-07 |
20160096816 | METHOD OF PREPARING INTERMEDIATE OF SALMETEROL - A method of preparing an intermediate of salmeterol (Compound 1, 2-amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol) includes: reacting compound 2 with 2-methoxypropene in a first organic solvent to produce a reaction solution including compound 3, compound 2 including a 2-bromo precursor of Compound 1; reacting compound 3 with a nitrogen source to produce compound 4; reacting compound 4 with sodium borohydride in a second organic solvent to produce compound 5; and debenzylating compound 5 by ammonium formate/palladium-carbon catalytic transfer hydrogenation in a third organic solvent to produce Compound 1. A method of preparing salmeterol includes preparing Compound 1, and reacting Compound 1 to prepare salmeterol. | 2016-04-07 |
20160096817 | TREATMENT OF INFLAMMATORY BOWEL DISEASE - Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I | 2016-04-07 |
20160096818 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS - Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal. | 2016-04-07 |
20160096819 | PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF - The present invention relates to a process for preparing N-substituted 1H-pyrazole-5-carboxylic acid compounds of the formula I-A and derivatives thereof, in particular the corresponding carbonylchloride compounds (acid chlorides). It also relates to the use of these acid chlorides for preparing anthranilamide derivatives that are useful pesticides. in which the variables are as defined in the claims and the specification comprising the steps of i) reacting a compound of the formula (II) with a base selected from combinations of a magnesium-organic compound having a carbon bound magnesium and a secondary amine and magnesium amides of secondary amines in the presence of a lithium halide, where the base is used in an amount sufficient to achieve at least 80% deprotonation of the compound of formula (II); and subjecting the product obtained in step (i) to a carboxylation by reacting it with carbon dioxide or a carbon dioxide equivalent, to obtain a magnesium salt of the compound of formula (I-A) and optionally aqueous workup to obtain the compound of the formula (I-A) as a free acid. | 2016-04-07 |
20160096820 | INHIBITORS OF INV(16) LEUKEMIA - This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (AML). The inv(16) fusion results in expression of the CBFβ-SMMHC fusion protein in the blood cells of afflicted patients. The present invention provides compounds which inhibit the function of both CBFβ and the CBFβ-SMMHC fusion. These compounds block the growth of an inv(16) leukemia cell line as well as increase its apoptosis, while showing minimal effects against non inv(16) cell lines. As a mechanism to develop inhibitors with selectivity for the CBFβ-SMMHC fusion protein, the present invention further provides dimeric derivatives of these compounds which show both increased potency as well as selectivity for CBFβ-SMMHC. These compounds show potent inhibition of an inv(16) leukemia cell line with minimal effects on non inv(16) cell lines. Analysis of the pharmacokinetics of the developed compounds has made it possible to improve the lifetime of the compound in the plasma of mice to a level commensurate with long-term treatment. | 2016-04-07 |
20160096821 | Chiral Synthesis of Pyrrolidine Core Compounds en route to Neuronal Nitric Oxide Synthase Inhibitors - A chiral synthesis of pyrrolidine compounds en route to selective neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable. | 2016-04-07 |
20160096822 | Novel Cannabinergic Nitrate Esters and Related Analogs - Biologically active cannabinergic nitrate esters and related analogs, process of preparation, pharmaceutical compositions and their methods of use as medicaments, pharmacological tools or biomarkers. Pharmaceutical compositions may include one or more of the nitrate ester compounds. Medicaments include one or more of the cannabinergic nitrate ester compounds and are useful in treating a variety of diseases. A method of treating, preventing or reducing the severity of a condition includes administering at least one of the disclosed nitrate ester compounds to an individual or animal in need thereof. | 2016-04-07 |
20160096823 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS - The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGFβR1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease. | 2016-04-07 |
20160096824 | Heterocyclic Compounds Useful for Kinase Inhibition - Provided herein are compounds useful for kinase inhibition. | 2016-04-07 |
20160096825 | Furanone Compounds as Kinase Inhibitors - The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as Raf kinase, especially BRAF kinase, inhibitors, which are useful therapeutic agents for treatment of Raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds. | 2016-04-07 |
20160096826 | CO-CRYSTALS OF LAPATINIB MONOACID SALTS - The present invention refers to co-crystals of monoacid salts of the pharmaceutical active ingredient named Lapatinib and to processes for the preparation thereof and medical uses. | 2016-04-07 |
20160096827 | TANK-BINDING KINASE INHIBITOR COMPOUNDS - Compounds having the following formula (I) and methods of their use and preparation are disclosed: | 2016-04-07 |
20160096828 | Indole-1-Carboxamides as Kinase Inhibitors - This invention is directed to a compound of Formula I | 2016-04-07 |
20160096829 | Substituted Isoxazole Derivatives - The present invention relates to compounds of the formula I | 2016-04-07 |
20160096830 | INHIBITORS OF LYSINE GINGIPAIN - The present invention relates generally to therapeutics targeting the bacterium | 2016-04-07 |
20160096831 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO - This disclosure relates to the field of molecules having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the following formula (“Formula One”). | 2016-04-07 |
20160096832 | KINASE INHIBITORS - The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | 2016-04-07 |
20160096833 | SUBSTITUTED 6-ARYL-IMIDAZOPYRIDINE AND 6-ARYL-TRIAZOLOPYRIDINE CARBOXAMIDE ANALOGS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 - Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention | 2016-04-07 |
20160096834 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF - The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors. | 2016-04-07 |
20160096835 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention relates to a compound of Formula I or IA and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof: | 2016-04-07 |
20160096836 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS - The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer. | 2016-04-07 |
20160096837 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS - The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | 2016-04-07 |
20160096838 | CRYSTALLINE FORM OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1H-PYRAZOL-3-YLAMINO)-6-ETHYL-1-METHYL-- 1,6-DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE-7-CARBOXAMIDE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS - Crystalline form, Form T2H1.5-4, of N,Ndicyclopropyl-4-(1,5-dimethyl-1 Hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (Compound (I)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising Form T2H1.5-4 of Compound (I) as well as a method of using the Form T2H1.5-4 of Compound (I) in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis. | 2016-04-07 |
20160096839 | PYRIMIDINONES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 2016-04-07 |
20160096840 | PROCESS FOR CONVERTING LUPANINE INTO SPARTEINE - The present invention relates to processes for preparing enantiopure Lupanine and Sparteine. | 2016-04-07 |
20160096841 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are Aminopurine Compounds having the following structures: | 2016-04-07 |
20160096842 | ANTI-INFLUENZA COMPOSITIONS AND METHODS - Disclosed are novel compounds comprising an imino-ribose derivative covalently linked to a carbocycle or heterocycle. Pharmaceutical compositions comprising the compounds of the invention are also described. Methods of inhibition, treatment and/or suppression of viral infections with the compounds of the invention are also described. The compositions or methods may optionally comprise one or more additional anti-viral agents. | 2016-04-07 |
20160096843 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the pyrazolo-pyrrolidin-4-one derivatives, and their use as BET inhibitors for the treatment of conditions or diseases such as cancer. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 2016-04-07 |
20160096844 | ORIDONIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO - Certain embodiments are directed to oridonin analogs or derivatives. In certain aspects, the derivatives are used as anticancer or anti-inflammatory agents. | 2016-04-07 |
20160096845 | SUPEROLEOPHOBIC AND/OR SUPERHYDROPHOBIC MATERIAL, PROCESS FOR PREPARING SAME AND APPLICATIONS THEREOF - The invention relates to a multilayer superoleophobic and/or superhydrophobic material comprising: on the one hand, a first constituent that is a conductive substrate or a substrate that has previously been rendered conductive (1): the surface of which is modified by chemical and/or physical treatment (2) and that incorporates a first adhesion-promoting conductive layer (3); or that incorporates a first adhesion-promoting conductive layer (3); and, on the other hand, at least one other constituent that is a superoleophobic and/or superhydrophobic polymer or copolymer layer (4, 5 or 6) composed of one or more monomers based on an aromatic or heteroaromatic ring substituted by one or more fluorocarbon and/or hydrocarbon chains. It is characterized in that the various constituents of said material comply with an increasing hydrophobicity gradient between the first layer deposited on the conductive substrate or substrate previously rendered conductive (1) and the last layer of said material. | 2016-04-07 |
20160096846 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 2016-04-07 |
20160096847 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS - Disclosed are azaindazole compounds of Formula (I): | 2016-04-07 |
20160096848 | SELECTIVE INHIBITORS FOR PROTEIN KINASES AND PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present invention provides a compound of formula (I) or the salt thereof: | 2016-04-07 |
20160096849 | CARBAZOLE DIOXAZINE PIGMENTS - The present disclosure relates to a benzoyl substituted carbazole-dioxazine pigment and its preparation. The process involves benzoylation of 3-nitro-N-ethylcarbazole in monochlorobenzene using benzoylchloride and ferric chloride to yield 3-nitro-6-benzoyl-N-ethyl carbazole, which on catalytic hydrogenation and subsequent condensation with chloranil and cyclisation yields benzoyl substituted carbazole-dioxazine pigment. | 2016-04-07 |
20160096850 | ALKYNYL ALCOHOLS AND METHODS OF USE - The invention relates to compounds of Formula (0): | 2016-04-07 |
20160096851 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF - The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) | 2016-04-07 |
20160096852 | Synthesis of 4-(pentafluorosulfanyl)benzenediazonium tetrafluoroborate and Analogs - 4-(pentafluorosulfanyl)benzenediazonium tetrafluoroborate salt was synthesized and isolated. The pentafluorosulfanyl salt was examined in a wide assortment of reactions to form novel SF | 2016-04-07 |
20160096853 | SYNTHETIC BLEND F-POSS COMPOSITIONS FORMED FROM MULTIPLE FEEDSTOCK MATERIALS - The present disclosure relates, in exemplary embodiments, to compositions of matter comprising synthetic blends of at least two feedstocks that produce a distribution of fluorinated polyhedral oligomeric silsesquioxane molecule structures. The present disclosure also relates, in exemplary embodiments, to methods of making such synthetic blends. | 2016-04-07 |
20160096854 | METHOD FOR SUPPRESSING HEAT DISCOLORATION OF LECITHIN - [PROBLEM] To provide a novel method for suppressing heat discoloration of lecithin and a novel lecithin or lecithin preparation having resistance to heat discoloration. | 2016-04-07 |
20160096855 | Method of Treating Colorectal Cancer - The present invention relates to the use of certain platinum compounds including [PtCb(cis-1,4-diaminocyclohexane)], or combinations of these compounds with a variety of other agents for treating and/or preventing the progression of colorectal cancer in mammals. In particular, the invention provides methods of treating and/or preventing oxaliplatin-refractory colorectal cancer in mammals. | 2016-04-07 |
20160096856 | METHOD OF PURIFYING IDRAPARINUX SODIUM - A method for the purification of idraparinux sodium includes: passing a solution including a crude idraparinux sodium through a column including a sodium ion exchange resin to obtain a first mixture; passing a solution including the first mixture through a gel chromatogaphy column to obtain a second mixture; and precipitating a purified idraparinux sodium from a solution including the second mixture. | 2016-04-07 |
20160096857 | Aldose-Ketose Transformation for Separation and/or Chemical Conversion of C6 and C5 Sugars from Biomass Materials - Systems for converting aldose sugars to ketose sugars and separating and/or concentrating these sugars using differences in the sugars' abilities to bind to specific affinity ligands are described. | 2016-04-07 |
20160096858 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 2016-04-07 |
20160096859 | ARBEKACIN DERIVATIVE, AND PRODUCTION AND USE THEREOF - It has been found that adding carbon dioxide or the like to a solution containing arbekacin free base makes it possible to produce arbekacin derivatives including arbekacin carbonate and carbamic acid of arbekacin. Moreover, it has been found that the arbekacin derivatives have a high stability, and that the use thereof enables efficient productions of highly-pure arbekacin free base and pharmaceutically acceptable salt thereof. | 2016-04-07 |
20160096860 | PREPARATION METHOD OF TRIHYDROXYETHYL RUTOSIDE - The present invention relates to a preparation method of trihydroxyethyl rutoside. In the method, rutin is firstly prepared into 7-monohydroxyethyl rutoside with a purity of greater than or equal to 98% by weight, and then 7-monohydroxyethyl rutoside is hydroxyethylated to give troxerutin having less than 2% of non-hydroxyethylated rutoside derivatives. The amount of 7,3′,4′-trihydroxyethyl rutoside in troxerutin is more than 80% by weight. The product is further purified so that 7,3′,4′-trihydroxyethyl rutoside with a purity of greater than or equal to 98% by weight could be obtained. | 2016-04-07 |
20160096861 | Novel galactoside inhibitor of galectins - Provided is a compound of the general formula (I): | 2016-04-07 |
20160096862 | TGR5 Modulators and Methods of Use Thereof - The invention relates to compounds of Formula A: | 2016-04-07 |
20160096863 | METHODS OF PREPARING INTERMEDIATE OF FLUTICASONE PROPIONATE - A method of preparing a thioic acid intermediate of fluticasone propionate includes: treating a 17β-[(N,N-dimethyl carbamoyl)thio]carbonyl compound in a solution including an alcohol and an alkali metal hydroxide, an alkaline-earth metal hydroxide, or a mixture thereof to cleave an amide from the 17β-[(N,N-dimethyl carbamoyl)thio]carbonyl compound; treating the solution to separate an aqueous portion; and adding an acid to the aqueous portion to obtain the thioic acid intermediate of fluticasone propionate. A method of preparing fluticasone propionate includes preparing the thioic acid intermediate of fluticasone propionate, and alkylating the thioic acid intermediate of fluticasone propionate to prepare the fluticasone propionate. | 2016-04-07 |
20160096864 | CATIONIC STEROIDAL ANTIMICROBIAL PRODRUG COMPOSITIONS AND USES THEREOF - Prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, or polymorphs thereof include a pharmaceutically and/or diagnostically active cationic steroidal antimicrobial (hereinafter “CSA”) compound or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof, and one or more cleavable groups (C.G.). Some embodiments include a CSA compound prepared in an inactive or less active form and that is capable of conversion to a fully active form upon administration to a subject, upon preparation of a pharmaceutical formulation containing the CSA composition, and/or upon exposure to physiological conditions. Pharmaceutical compositions include the prodrug or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof and one or more pharmaceutically acceptable excipients. Methods of treatment of bacterial infections in a patient in need utilize prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, polymorphs thereof and/or the pharmaceutical compositions described herein. | 2016-04-07 |
20160096865 | Peptide-Silica Hybrid Materials - The invention relates to novel peptide-silane “hybrid block” molecules, to the synthesis thereof and to the use of same for producing novel peptide-silica hybrid materials that can be used in various applications. | 2016-04-07 |
20160096866 | POTENT COMPSTATIN ANALOGS - Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. Methods of making and using the compounds are also disclosed. | 2016-04-07 |
20160096867 | CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS - The present invention relates to γ-PNA monomers according to Formula I where substituent groups R | 2016-04-07 |
20160096868 | Mussel-inspired bioactive surface coating composition generating silica nanoparticles - The present invention relates to a fusion protein comprising a mussel adhesive protein and a silica-binding peptide linked to the mussel adhesive protein, a silica nanoparticle a silica connected to the fusion protein, a fusion protein-silica nanoparticle complex comprising the silica nanoparticle having bioactivity and adhesiveness for cell proliferation and accelerating the differentiation, a surface coating composition including the complex, its use, and a method of coating a surface using the surface coating composition. | 2016-04-07 |
20160096869 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF - Compositions, formulations and kits comprising chlorotoxin conjugate compounds are provided, including native and modified variants of chlorotoxin peptide conjugated to reporter molecules including fluorescent dyes. Methods of detecting and treating cancers and tumors with chlorotoxin conjugate compounds are also provided, including methods of imaging tumor tissues and cells. Dosing and pharmacokinetic profiles for therapeutic and diagnostic applications using chlorotoxin conjugate compounds are also provided. | 2016-04-07 |
20160096870 | COMPLEMENT INHIBITORS - The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases. | 2016-04-07 |
20160096871 | Methods and Reagents for Treatment of Age-Related Macular Degeneration - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 2016-04-07 |
20160096872 | METHODS FOR PRODUCING PEPTIDES USING ENGINEERED INTEINS - The present invention provides a method for producing peptides by recombinant means. The peptides are expressed as part of a fusion protein comprising the target peptide and an engineered intein. The invention also provides the engineered inteins, fusion proteins comprising these, and DNA constructs coding for these fusion proteins. Upon thiol-induced cleavage of the fusion protein the carboxy-terminal a-thioester of the target peptide is obtained. The carboxy-terminal ct-thioester can in principle react with any nucleophile and the strategy therefore allows a wider range of carboxy-terminal modifications such as chemical ligation, bioconjugation, or amidation. The engineered inteins of the present invention are minimized in size and has a cysteine mutation in the position corresponding by alignment to position 3 of Mxe GyrA intein (SEQ ID NO:1) leading to increased expression levels of the fusion protein and higher yields of the isolated target peptide, thus making the method of the invention suitable for production scale. | 2016-04-07 |
20160096873 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins. The invention additionally provides methods of identifying and making such improved polypeptides. | 2016-04-07 |
20160096874 | MRG RECEPTOR MODULATORS - The present invention is in the field of molecular biology, more particularly, the present invention relates to drug screening, assay development and identification and use of modulators for G-protein coupled receptor/ligand pair MRGX2/CXCL14 within drug discovery. | 2016-04-07 |
20160096875 | CODON OPTIMIZED IL-15 AND IL-15R-ALPHA GENES FOR EXPRESSION IN MAMMALIAN CELLS - The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-15 sequence. | 2016-04-07 |
20160096876 | COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 2016-04-07 |
20160096877 | APOE PEPTIDE DIMERS AND USES THEREOF - The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed. | 2016-04-07 |
20160096878 | FIBROIN-DERIVED PROTEIN COMPOSITION - The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa. | 2016-04-07 |
20160096879 | Viscosity-Reducing Excipient Compounds for Protein Formulations - The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. | 2016-04-07 |
20160096880 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 2016-04-07 |
20160096881 | MEANS AND METHODS FOR PRODUCING HIGH AFFINITY ANTIBODIES - The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures. | 2016-04-07 |